Invokana: new SGLT2 inhibitor for type II diabetes

Janssen-Cilag has launched Invokana (canagliflozin) for the treatment of type II diabetes inadequately controlled with diet and exercise.

by
Invokana (canagliflozin) is given once daily at a starting dose of 100mg, increasing if necessary to 300mg once daily in patients with CrCl ≥60ml/min
Invokana (canagliflozin) is given once daily at a starting dose of 100mg, increasing if necessary to 300mg once daily in patients with CrCl ≥60ml/min

Sign in to continue

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package